Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab TDM in Perianal Fistulizing Crohn’s Disease
KCT0008205Phase 4Terminated
- Sponsor
- Celltrion Pharm
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of infliximab in Crohn's disease, sponsored by Celltrion Pharm. Started Mar 2023; status: terminated.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on KCT0008205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008205.